Search
  • martind

OniX looking for ideas for funding, partnering and investments

Updated: Oct 17

October 16, 2020

Current areas of interest by OniX Members.

Note: new members will be joining soon.


OniX members are actively looking for projects in these areas.

NEURODEGENERATIVE

  • Targeted indications: A neurodegenerative disease that has been designated as an intractable disease in Japan or is designated as a rare disease in the United States

  • Proposals with specific drug candidates (small molecules, peptides, antibodies, or proteins, etc.) are preferred.

  • New drug candidates must be in the preclinical stages of development.

  • Proposals with pharmacological data obtained using translational animal models or human cells are desirable.

AUTOIMMUNE

  • Targeted indications: Intractable or refractory autoimmune disease (Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Syndrome, IBD, Diabetes, etc.).

  • Proposals with specific drug candidates (small molecules, peptides, antibodies, or proteins, etc.) are preferred.

  • New drug candidates must be in the preclinical stages of development.

  • It is desirable that the target molecule and mechanism of action have been clarified.

  • Proposals with pharmacological data obtained using disease animal models are desirable.

  • Proposals that have data or ideas with superiority over existing therapies and other therapies in development are preferred

CRITICAL CARE MEDICINE

  • Targeted indications: Acute respiratory distress syndrome (ARDS), severe infection (including bacteremia, endocarditis, and severe pneumonia), and acute kidney injury (AKI).

  • Gene therapies, cell therapies, and therapeutic devices shall not be considered for this program.

  • New drug candidates must be in the preclinical stages of development.

  • Proposals should have data explaining the drug's efficacy and mechanism of action, as well as data showing the expected drug positioning and features.

  • It is desirable to have in vivo data (efficacy, ADME and toxicity)

BONE, CARTILAGE AND MUSCLE

New drug targets which are expected to provide a new therapeutic approach for rare and intractable bone diseases

  • Targeted indications: rare and intractable bone diseases (e.g., ossification of posterior longitudinal ligament (OPLL), fibrodysplasia ossificans progressiva (FOP), osteonecrosis, or osteogenesis imperfecta).

  • Proposal must be between Lead-to-Candidate stage and IND-ready stage (drug repositioning is also acceptable).

  • It is desirable to have in vivo or in vitro efficacy data.

New drug candidates for rare and intractable cartilage diseases

  • Targeted indications: rare and intractable cartilage diseases (e.g., achondroplasia including hypochondroplasia and chondrodystrophy)

  • Proposal must be between Lead-to-Candidate stage and IND-ready stage (drug repositioning is also acceptable).

  • Drug target molecules should be novel targets.

  • In vitro drug efficacy and in vivo drug efficacy data are preferred, although strong proposals with solid plans for generating such data may be considered.

New drug candidates for articular cartilage damage and degeneration

  • Targeted indications: articular cartilage damage and degeneration

  • Proposal must be between Lead-to-Candidate stage and IND-ready stage (drug repositioning is also acceptable).

  • Pharmaceuticals or medical materials (including microfracture and cell therapy) are desirable.

  • Local administration is preferred.

  • Proposal with data suggesting safety, pharmacokinetics and efficacy in vivo is preferable.

New drug targets or drug seeds in muscle-related diseases

  • Target indications: Sarcopenia, Cancer cachexia, Muscle disuse atrophy, and refractory muscle diseases (e.g. muscular dystrophy, myasthenia gravis, etc.).

  • Proposals with specific drug candidates (small molecules, peptides, antibodies, proteins or nucleic acid etc.) are preferred.

  • New drug candidates must be in the preclinical stages of development.

  • Proposals with pharmacological data obtained using translational animal models or human cells are desirable.

  • Target tissues and organs are not limited to muscle. Drug target molecules that can be therapeutics to muscle-related diseases acting on muscle even if it is secondary effect are also appropriately evaluated. However, anti-cancer drugs for cancer cachexia is out of scope.

  • Drug target molecules that can increase muscle mass and muscle strength, and enhance muscle performance based on the concept of senescence inhibition/aging control, such as the removal of senescence cells or the NAD+/Sirtuin pathway activation, either of which affects to increase muscle mass/strength, or longevity-regulatory factors which potentially affect to increase in muscle mass/strength are desirable.

More soon on the following areas:

  • Animal Health: Animal Genetics

  • Neurodegenerative Diseases: Alzheimer's, Parkinson, and others

  • Liver, Kidney, Pancreatic Diseases

  • Cardiovascular Diseases

  • Metabolic Diseases

  • Skin Diseases

  • Rare Diseases

  • All Types of Cancers

To submit not-confidential abstracts go to: https://www.onixhub.com/submit - it takes 5 minutes to submit an idea. An idea can be a submitted, funded or unfunded non-confidential abstract of a grant application, a technical summary of a project from a startup or biotech company, a project to be out-licensed or other.

Please send any questions to ask@onixhub.com

43 views

© 2018 Online Ideas Exchange Hub — All Rights Reserved.

  • Facebook
  • Twitter